Fulcrum Therapeutics (FULC) Preferred Dividend Payments (2018 - 2019)
Fulcrum Therapeutics' (FULC) quarterly Preferred Dividend Payments came in at $796000.0 in Q3 2019, down 57.16% year-on-year from $1.9 million in Q3 2018, and down 75.81% on a QoQ basis from $3.3 million in Q2 2019.
Fulcrum Therapeutics (FULC) Preferred Dividend Payments (2018 - 2019) Analysis & Trends
Fulcrum Therapeutics (FULC) has 2 years of Preferred Dividend Payments data on file, last reported at $796000.0 in Q3 2019.
- On a quarterly basis, Preferred Dividend Payments fell 57.16% year-over-year to $796000.0 in Q3 2019; TTM through Dec 2019 was $7.1 million, a N/A change from a year earlier, with the FY2019 full-year figure at $7.1 million, up 8.68% from the prior year.
- Preferred Dividend Payments for Q3 2019 stood at $796000.0, down from $3.3 million in the prior quarter.
- Over the last five years, Preferred Dividend Payments for FULC reached as high as $3.3 million in Q2 2019 and fell as low as $796000.0 in Q3 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Pref Dividends (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Fulcrum Therapeutics | 285.43 Mn | 285.43 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | 796,000.00 |
| Jun 30, 2019 | 3.29 Mn |
| Mar 31, 2019 | 3.04 Mn |
| Dec 31, 2018 | 2.82 Mn |
| Sep 30, 2018 | 1.86 Mn |
| Jun 30, 2018 | 1.05 Mn |